AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pfizer's $13.65 Billion Trading Day Marks 41st Ranking Amid Obesity Pill Setback
Generated by AI AgentAinvest Market Brief
Monday, Apr 14, 2025 7:23 pm ET1min read
On April 14, 2025, Pfizer's trading volume reached $13.65 billion, ranking 41st in the day's stock market.
(PFE) rose by 0.96%, marking two consecutive days of gains, with a total increase of 2.45% over the past two days.Pfizer has terminated the development of its obesity pill, danuglipron, following a clinical trial participant experiencing signs of liver injury. This decision comes after the company had previously announced in 2023 that it would stop testing danuglipron as a twice-daily pill. The discontinuation of danuglipron adds to a series of setbacks in Pfizer's efforts to enter the growing market for GLP-1 drugs.
Pfizer's Chief Scientific Officer, Chris Boshoff, expressed disappointment over the discontinuation but emphasized that cardiovascular and metabolic diseases remain important areas of focus for the company. The company has decided to no longer continue research on the molecule danuglipron, shifting its focus to other potential treatments.
Ainvest Market Brief
Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.
Latest Articles
Morning Market Pulse: Trump’s Federal Pay Raise & Japan’s Policy Shift Drive Pre-Market Moves
Dec.19 2025
What to Trade Today: Volatility and Inflows Drive Pre-Market Moves
Dec.19 2025
U.S. Corporate Actions | Ticker Changes and Dividend Announcements Highlight Activity
Dec.19 2025
Morning Market Pulse: Trump’s Marijuana Rescheduling and AI Policy Shifts
Dec.18 2025
What to Trade Today: Mixed Macro Signals and Short-Term Glimmers in the Diagonal
Dec.18 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet